What is the appropriate treatment for seronegative autoimmune hepatitis with advanced fibrosis and concurrent cholangitis?

Treatment of Seronegative Chronic Active Hepatitis with Advanced Fibrosis and Cholangitis

For seronegative autoimmune hepatitis with advanced fibrosis and concurrent cholangitis (overlap syndrome), initiate combination therapy with predniso(lo)ne at 0.5-1 mg/kg/day plus azathioprine (50 mg/day initially, titrating to 1-2 mg/kg/day) or mycophenolate mofetil (1.5-2 g/day), combined with ursodeoxycholic acid for the cholestatic component. 1, 2

Diagnostic Considerations

The presence of cholangitis with seronegative AIH suggests an AIH-PSC overlap syndrome or AIH-PBC overlap syndrome, which requires careful characterization:

• Seronegative AIH occurs in approximately 10% of AIH cases and presents diagnostic challenges 3
• Consider IgG4-associated AIH in seronegative cases with cholangitis, as this represents a distinct entity requiring specific evaluation 4
• Histology is critical: look for interface hepatitis with plasma cell infiltration (AIH features) plus bile duct injury, ductopenia, or onion-skin fibrosis (cholangitis features) 5, 6
• Cholangiography may initially appear normal in early overlap syndrome, with characteristic changes developing during follow-up 7

Treatment Algorithm

First-Line Immunosuppression

The 2025 EASL AIH guidelines provide clear direction 1:

• Predniso(lo)ne: Start at 0.5 mg/kg/day for moderate disease, escalating to 1 mg/kg/day for severe/advanced disease with fibrosis
• Azathioprine: Begin at 50 mg/day (ideally 2 weeks after corticosteroid initiation if bilirubin <6 mg/dl), titrate to 1-2 mg/kg/day
• Alternative: Mycophenolate mofetil 1.5-2 g/day if azathioprine is contraindicated (note: MMF is teratogenic and requires counseling)

Adding Cholestatic Component Treatment

For the concurrent cholangitis 2:

• Ursodeoxycholic acid (UDCA) should be added to the immunosuppressive regimen
• The 2022 EASL PSC guidelines specifically recommend this combination for PSC-AIH overlap syndrome 2
• UDCA addresses the cholestatic component while immunosuppression targets the hepatitic inflammation

Corticosteroid Tapering Strategy

• Taper should be individualized based on biochemical response 1
• Rapid tapering (5-10 mg every 1-2 weeks) is desirable once response is achieved
• Monitor ALT, IgG levels, and clinical symptoms closely during tapering

Critical Prognostic Considerations

Important caveat: Despite treatment response, overlap syndromes have a more aggressive natural history:

• Fibrosis progression occurs in the majority of patients despite immunosuppression 7
• In one long-term study, 12 of 16 patients with AIH-PSC overlap developed cirrhosis over 12 years despite treatment 7
• Immunosuppression combined with UDCA improves biochemical markers but cannot prevent long-term progression to cirrhosis in most patients 7

Advanced Fibrosis Considerations

Given the presence of advanced fibrosis, additional management is essential:

• Bone density assessment (DEXA) at baseline and during follow-up, as corticosteroids and cirrhosis increase osteoporosis risk 1
• Ophthalmologic evaluation for intraocular pressure monitoring due to long-term corticosteroid use 1
• Screening for autoimmune comorbidities: thyroid disorders (TSH, T4, anti-thyroid antibodies) and celiac disease 1
• Hepatocellular carcinoma surveillance if cirrhosis develops

Monitoring Response

Track the following parameters:

• Biochemical response: Normalization of ALT and IgG levels
• Cholestatic markers: Alkaline phosphatase and gamma-glutamyl transferase levels correlate with corticosteroid responsiveness 8
• Histologic follow-up may be necessary to assess treatment response and fibrosis progression
• Consider non-invasive markers like transient elastography for monitoring fibrosis 9

Refractory Disease Management

If first-line therapy fails (10-25% of AIH cases) 10:

• Rule out concurrent conditions: metabolic dysfunction-associated steatotic liver disease, alcohol use, viral hepatitis
• Second-line options include higher-dose steroids, cyclosporine, tacrolimus, or biologics (infliximab, rituximab)
• Liver transplantation may be necessary for acute severe AIH or acute-on-chronic liver failure

Common Pitfalls to Avoid

• Don't delay treatment waiting for positive autoantibodies in seronegative cases with compatible histology
• Don't miss IgG4-associated disease: Check IgG4 levels and IgG4 staining on biopsy in seronegative cases 4
• Don't use immunosuppression alone for overlap syndromes—UDCA is essential for the cholestatic component 2
• Don't assume normal cholangiography excludes PSC overlap—early bile duct changes are often missed, and repeat imaging may be needed 7